Invida: John Graham explains how Invida represents a single point of entry into the Asia Pacific markets and Invida's Product portfolio




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Invida: John Graham explains how Invida represents a single point of entry into the Asia Pacific markets and Invida's Product portfolio
Released on: September 07, 2011. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
  • Summary
  • Transcript
  • Participants
  • Company
In this episode of PharmaTelelvision News Review, Fintan Walton talks to John Graham, CEO of Invida.
Invida: A commercialisation expert company of Asia Pacific region
Fintan Walton:
Hello and welcome to PharmaTelevision News Review here at BIO 2011 in Washington. On this show I have John Graham, who is CEO of a company called Invida, welcome to the show.
John A. Graham:
Good afternoon.
Fintan Walton:
John, Invida as I said is a Asia Pacific company I understand it's about 5-years old, could you tell us the origins of the company and how that came about?
John A. Graham:
Yes Invida as you said was started in 2005, it's a joint investment between three major players in the healthcare investment community, Temasek which is the one of sovereign wealth funds of the Singapore government, Quintiles the pharmaceutical services company and Zuellig Pharma which is the largest drug distributor in Asia and the three companies came together to form Invida in 2005 [PharmaDeals ID = 20665] as a commercialization specialist to cover the Asia Pacific region.
Fintan Walton:
When you talk about the Asia Pacific region what countries are we including in that region?
John A. Graham:
We cover all 13 major markets in Asia, ex Japan, so if you think of it as a inverted triangle from India, to China and down to Australia, we cover all the major markets in that area.
Invida's Product portfolio
Fintan Walton:
And you already have products that you sell into that market?
John A. Graham:
Absolutely we have revenues in 2010 for around $220 million. We have a variety of revenue streams, we have our own proprietary products, I wish our products that we have been bought or licensed and have brought them to market ourselves, we also partner significantly with a number of mid to large size pharma companies in Europe and US and we have a small contract sales business.
Fintan Walton:
So in that combination you've already obviously said you've inherited these products presumably from which organization you head that's from Zuellig was it?
John A. Graham:
We've made a number of acquisitions early on in the life of Invida a number of those products came from Lilly, but most significantly we made an acquisition of the Valeant [PharmaDeals ID = 29811] Asia Pacific portfolio and operations in Asia Pacific in 2008 which provided us with about 13 new brands and we have continued to build those brands in the Asia Pacific region and launch new brands from that portfolio.
Invida represents a single point of entry into the Asia Pacific markets
Fintan Walton:
Okay, as you already indicated your plan is to build up that portfolio, why should companies wanna partner with you to get an access into Asia?
John A. Graham:
Well today we represent a single point of entry into the Asia Pacific markets, if you don't partner with a large pharmaceutical company in Asia you either have to work with us as a unique entity within the Asia Pacific region or to access these markets you have to partner and seek partners in individual countries do the due diligence and do the deal and then manage those partners and that becomes quite a task for small to medium size companies when they are sitting in Europe.
Fintan Walton:
Right, and one of your partners is Quintiles, does Quintiles bring more than just simply being a shareholder in the organization?
John A. Graham:
Yes they own 30% of the company [PharmaDeals ID = 20665].
Fintan Walton:
Yes, but do they offer more than that?
John A. Graham:
Obviously these companies have a lot of access to business development opportunities and very often Quintiles will help us find opportunities through their own activities.
Growth strategy over next five years
Fintan Walton:
Okay, good and for a company like yours to grow obviously you need more products, what are your ambitions for the company then? What do you see yourselves doing over the next four to five-years?
John A. Graham:
So over the last five-years we've grown quite rapidly through both inorganic and organic growth. Our five-years CAGR is about 31% which is very significant and we hope to be able to continue growing at that rate, there are lot of opportunities in Asia currently both in India and China, but also in some of the smaller countries in Asia such as the Vietnam, Philippines, Indonesia where we have very strong presence and we intend to continue growing in those countries working significantly with, in the room of partnering really core to our business is the idea of partnering with small to medium size companies based in the US or in Europe that don't have the infrastructure or perhaps the resources to commercialize that products in Asia and we offer really a one stop shop for those kinds of companies to exploit the opportunities today.
Fintan Walton:
Right, there are lots of emerging companies in China and in Asia particularly is focused on selling products rather than just being innovative biotech type companies, would they become sort of future targets for acquisition is that part of your overall strategy?
John A. Graham:
Possibly yes, as we expand our presence in some of the larger markets we are always on the lookout for opportunities to acquire companies that can provide us with an infrastructure or with complimentary resources that we don't currently have in those markets. So key to that expansion strategy would be obviously in china and in India, but also in other markets such as Indonesia for instance.
Business model
Fintan Walton:
Right, and just terms of going back to your business model do you see that business model changing over the next five-years is that are you gonna just sustain that similar model or do you have ambitions to change that business model?
John A. Graham:
I think as the company develops and grows within Asia we will become more recognized as a specialty pharma company than as a service base company and that's really our goal and we intend to grow through partnering and through having real expertise in Asia, we don't have any ambition today to expand outside of Asia as I am very often asked whether we will go to Latin America or to the middle east, probably really want to go deep in Asia understand the Asian markets, understand the Asian consumers and their needs and become experts in that marketplace.
Fintan Walton:
John Graham, thank you very much indeed for coming on the show.
John A. Graham:
Thank you.
Fintan Walton
Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).
John A Graham
CEO
John A. Graham is currently Chief Executive Officer at Invida. John brings more than 25 years of executive experience in biotech, pharmaceuticals, and healthcare consulting to his role as Chief Executive Officer at Invida. He has focused the company's business development and marketing efforts, while using his international experience to bring companies and products from around the world into the Asia Pacific arena. John A. Graham has held senior management positions in Europe, the United States, and Latin America. Prior to joining Invida, he was President of Paramount Corporate Development, a biotech venture firm in New York. Earlier he was a Principal at Ernst & Young, where he built the Life Sciences Advisory Practice around business analytics and marketing effectiveness. Prior to his role at Ernst & Young he was Managing Director of Genzyme's operations in Germany and Switzerland, responsible for Genzyme's diversified business portfolio in those countries. John started his career with Aventis, where he spent 18 years in global commercial leadership positions including regional responsibilities in Latin America, Head of Global Diabetes, and VP of New Products. John graduated from the Imperial College of Science and Technology in London with a BSc (Hons) in Biochemistry.
PharmaVentures
PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.
Invida
Invida improves the lives of patients in Asia by commercializing differentiated pharmaceutical products of superior quality - the result of which will allow all Invida stakeholders to prosper. This is done through proven brand marketing and sales know-how, strong expertise across a number of key therapeutic categories and deep experience in all critical Asian markets. Comprehensive functional capabilities provide rapid market access delivered by our passionate team of professionals. With more than 3,500 employees in 13 markets in Asia Pacific, Invida operates across the commercial value chain from regulatory approval and product launch to lifecycle management. Invida manages a portfolio of proprietary healthcare brands as well as licensed products from emerging and large, multinational biopharmaceutical companies. Partnering is a critical component of Invida's business model and collaborates closely with our partners in developing effective strategies and put our extensive experience behind maximizing the potential of the assets entrusted to us.